Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.16 CAD | -5.88% | -13.51% | -11.11% |
Apr. 15 | RBC Capital Markets Gives Nutrien Outperform Rating, US$70 Price Target | MT |
Mar. 28 | North American Morning Briefing : Stocks Set for -2- | DJ |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 8.435 | 7.17 | 10.33 | 17.29 | 11.72 | 9.591 |
Enterprise Value (EV) 1 | -2.069 | -0.2793 | 5.551 | 15.49 | 8.041 | 7.295 |
P/E ratio | -0.95 x | -2.32 x | -3.01 x | -7.88 x | -5.95 x | -6.74 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | 0.51 x | 0.11 x | -2.28 x | -8.09 x | -5.23 x | -5.48 x |
EV / FCF | 0.87 x | 0.15 x | -3.73 x | -6.86 x | -5.91 x | -6.82 x |
FCF Yield | 115% | 671% | -26.8% | -14.6% | -16.9% | -14.7% |
Price to Book | 0.59 x | 0.63 x | 1.3 x | 3 x | 1.49 x | 1.48 x |
Nbr of stocks (in thousands) | 42,175 | 42,175 | 42,175 | 42,175 | 53,284 | 53,284 |
Reference price 2 | 0.2000 | 0.1700 | 0.2450 | 0.4100 | 0.2200 | 0.1800 |
Announcement Date | 3/22/19 | 3/23/20 | 3/19/21 | 3/30/22 | 3/28/23 | 3/25/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -4.087 | -2.442 | -2.435 | -1.916 | -1.539 | -1.332 |
EBIT 1 | -5.039 | -3.24 | -3.379 | -2.49 | -2.613 | -1.931 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.018 | -3.091 | -3.429 | -2.193 | -1.728 | -1.422 |
Net income 1 | -6.018 | -3.091 | -3.429 | -2.193 | -1.728 | -1.422 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.2112 | -0.0733 | -0.0813 | -0.0520 | -0.0370 | -0.0267 |
Free Cash Flow 1 | -2.372 | -1.874 | -1.489 | -2.259 | -1.36 | -1.07 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/22/19 | 3/23/20 | 3/19/21 | 3/30/22 | 3/28/23 | 3/25/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 10.5 | 7.45 | 4.78 | 1.8 | 3.68 | 2.3 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -2.37 | -1.87 | -1.49 | -2.26 | -1.36 | -1.07 |
ROE (net income / shareholders' equity) | -37.5% | -24.1% | -35.6% | -32% | -25.3% | -19.8% |
ROA (Net income/ Total Assets) | -17.7% | -13.2% | -16.8% | -15.9% | -17.9% | -13.2% |
Assets 1 | 33.94 | 23.5 | 20.39 | 13.83 | 9.669 | 10.76 |
Book Value Per Share 2 | 0.3400 | 0.2700 | 0.1900 | 0.1400 | 0.1500 | 0.1200 |
Cash Flow per Share 2 | 0.2500 | 0.1800 | 0.1100 | 0.0400 | 0.0700 | 0.0400 |
Capex | - | 0.08 | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/22/19 | 3/23/20 | 3/19/21 | 3/30/22 | 3/28/23 | 3/25/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-11.11% | 6.23M | |
+15.18% | 38.38B | |
-.--% | 11.15B | |
-4.79% | 7.3B | |
+6.68% | 6.87B | |
-3.91% | 5.91B | |
-10.60% | 5.6B | |
-4.54% | 5.54B | |
+31.35% | 5.19B | |
-13.69% | 4.58B |
- Stock Market
- Equities
- KRN Stock
- Financials Karnalyte Resources Inc.